ClinicalTrials.gg
CompletedNCT00196430Updated Sep 20, 2005

Study About Effectiveness of Silver-Containing Textiles for Treatment of Acute Neurodermatitis

A Phase 3 interventional study of silver-contained textiles and corticosteroid in Neurodermatitis, sponsored by University Medicine Greifswald. Completed at 1 site in Germany. Open to participants aged 2 Years to 70 Years. Per ClinicalTrials.gov, last updated 2005-09-20.

Sponsored by University Medicine Greifswald · Phase 3, Interventional, and Treatment

Phase
Phase 3
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
2 Years to 70 Years
Sex
All
01

Study summary

The purpose of this study is to investigate whether the treatment of acute neurodermitis with silver-contained textiles is equivalent or more effective to the conservative exogenous treatment with a corticosteroid. Secondary aim is to define skin comfortability of the textiles.

02

Conditions studied

  • Neurodermatitis

Browse trials for

03

In context

Neurodermatitis

22 studies on the registry are indexed under Neurodermatitis; 3 are open to participants now.

This study's enrollment of 32 is below the median of 44 across 22 interventional studies indexed under Neurodermatitis.

Browse Neurodermatitis studies →

Lead sponsor

University Medicine Greifswald is the lead sponsor of 152 studies on the registry; 22 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of acute Neurodermitis
  • Age: 2-70 years
  • Patients are mobile
  • Patient's information and willingness to participate

Exclusion criteria

Exclusion Criteria:

  • Acute viral infection (herpes zoster, eczema herpeticum)
  • Acute staphylodermas
  • Other skin-diseases affecting outcomes of intervention (e.g. psoriasis)
  • Current UV-Treatment
  • Current other or immunomodulated Therapy
  • Current antimicrobial Therapy (e.g. antibiotics)
  • Severe general diseases (e.g. melanoma, renal insufficiency, diseases)
  • Pregnancy
  • Fertile females without effective
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single
Enrollment
32 participants

Interventions

  • Devicesilver-contained textiles
  • Drugcorticosteroid
06

What researchers measure

Primary outcomes

  1. SCORAD at days -3,0,7,14,28,56 for every group

Secondary outcomes

  1. Influence of silver containing textiles in reducing bacterial skin colonization (especially Staph. aureus)

  2. Consumption of corticosteroids at days 0-28

  3. Consumption of corticosteroids at days 28-56

  4. Pruritus under textiles

  5. Evaluation of quality of life

07

Study locations

1 site
  • Clinic and Polyclinic of Dermatology, Ernst-Moritz-Arndt-University of Greifswald
    Greifswald, Fleischmannstr. 42-44 17475, Germany
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 20, 2005, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00196430
Collaborators
Julius Zorn GmbH, Aichach, Germany
First posted
Sep 20, 2005
Start date
Jan 2004
Completion
Aug 2004
Last update
Sep 20, 2005

Study contacts

Michael Jünger, Prof. Dr.
principal investigator · Clinic and Polyclinic of Dermatology, University of Greifswald
Andrea Ladwig
study chair · Clinic and Polyclinic of Dermatology, University of Greifswald
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2005. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion